NA-931 is a igf-1/glp-1/gip/glucagon agonist used for weight loss. NA-931, also called Bioglutide, is an experimental obesity compound from Biomed Industries of San Jose. The company describes it as a first-in-class quadruple receptor agonist acting at the IGF-1, GLP-1, GIP and glucagon receptors, given as a once-daily capsule. It is the compound behind the 'GLP-4' label that sellers have put on injectable vials, a description that fits neither the capsule nor the company.

How much water do I add to NA-931?

You can reconstitute NA-931 with 0.5, 1, or 2 mL of bacteriostatic water. Each option produces a different concentration and syringe draw for the same dose. Use the calculator to see which is easiest to measure.

What does NA-931 cost per dose?

Cost per dose depends on vial size, price paid, and your dose. Enter your vendor's price in the NA-931 calculator to see cost per dose and monthly cost.

What is the reference dose for NA-931?

The commonly referenced range is Up to 150 mg once daily in the phase 2 trial, taken daily. This is reference information, not a recommendation. Talk to a licensed clinician.

What are the side effects of NA-931?

Reported side effects of NA-931 include: The company reports the phase 2 was generally well tolerated; no peer-reviewed safety data has been published.; Material sold in vials as NA-931 or Bioglutide has repeatedly tested as something else entirely: a 154 dalton cyclic dipeptide in one case, a retatrutide and cagrilintide blend in another, and a GHRP-6 analogue in a third.. Severity and frequency vary by person and dose.

Who should not take NA-931?

NA-931 is generally not appropriate for: Not legally available outside clinical trials, so no prescriber is assessing whether it suits you; Pregnancy, or trying to become pregnant. Talk to a licensed clinician before starting.

New?New to peptides?Start here →

Decoding

NA-931_Dosage, benefits & legal status

Also known as Bioglutide, bioglutide, GLP-4, glp-4, GLP4, NA931, na 931

By the Peptide Decoding Editorial Team

Published September 23, 2026

An experimental daily obesity capsule that has also become one of the most-faked names in the supply chain.

Weight lossIGF-1/GLP-1/GIP/glucagon agonistInvestigationalHigh-risk

InGLP-1 agonists

DoseUp to 150 mg once daily in the phase 2 trial

FrequencyDaily

RouteBy mouth (oral capsule)

StatusInvestigational

MixYour choice, calculate it

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

See how this dose compares across the library →

What is NA-931?

Plain language first. The technical label stays, but it never stands alone.

Overview

A once-daily obesity capsule in clinical trials, claimed to hit four hormone receptors at once. The catch: it only exists as a capsule from its developer, and every injectable vial tested under this name has been a different compound.

The technical version

NA-931 (Bioglutide) is an orally active small-molecule described by Biomed Industries as a quadruple agonist of the IGF-1, GLP-1, GIP and glucagon receptors, in phase 2 and 3 development for obesity.

What it's used for

It is being developed for weight loss. The company's 13-week phase 2 in adults with obesity reported dose-dependent weight reduction up to 13.8% at 150 mg daily against placebo, presented at a conference and by press release, not yet in a peer-reviewed journal.

How does NA-931 work?

What it does in the body, and where.

NA-931 is described by its developer as a quadruple agonist: it is claimed to switch on four receptors at once, adding IGF-1 to the GLP-1, GIP and glucagon targets retatrutide hits.

01
GLP-1, GIP and glucagon cover appetite and burn
The same three levers as the injectable triple agonists: eat less, and spend more energy at rest.
02
IGF-1 is the claimed fourth target
The company says this protects muscle during weight loss. No body-composition data supporting that claim has been published.
03
It is a capsule, not an injection
An orally active small molecule taken once daily. Any vial sold for injection under this name is not the company's product.

Receptors

Hits 4 receptors at once.

What else is it used for?

Each group carries its own evidence level.

Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

Weight loss

Investigational

Human trialThe company's 13-week phase 2 reported dose-dependent weight reduction up to 13.8% at 150 mg daily against placebo, presented at EASD in September 2025 and by press release.
Human trialA separate 28-day dose-escalation study in 74 participants (NCT06615700, published as a Diabetes conference abstract) reported dose-dependent weight reduction up to 6.4%, with up to 63% of treated participants losing at least 5% of body weight. Gastrointestinal events were reported as mild, and no nausea or vomiting was reported among treated subjects in that study.
Human trialPhase 3 trials of NA-931 alone and alongside semaglutide or tirzepatide are registered. No peer-reviewed results have been published.

Study

Biomed Industries, EASD 2025 press release

What is actually in the vials

Investigational

lab-analysisRaw material sold as NA-931 tested by proton NMR and mass spectrometry came back as cyclo(Pro-Gly), a 154 dalton cyclic dipeptide also called NA-831, one digit apart in the developer's own naming.
lab-analysisA product sold as Bioglutide tested as a blend of retatrutide and cagrilintide; a third sample was [D-Lys3]-GHRP-6. Three samples, three different compounds.

Often left out

The 13.8% weight loss figure is the company-reported top-dose result at 150 mg daily, announced by press release and conference presentation, not a peer-reviewed average. And "GLP-4" is a seller label, not a real receptor class; the developer has never sold NA-931 as an injectable.

Study

Independent analytical testing reports

Compound field notes

At a glance

Four things to know about NA-931

Evidence

Investigational

How much, and do you cycle it?

The range, and whether you take breaks.

Up to 150 mg once daily in the phase 2 trial, daily. Not cycled.

What does it cost?

Typical dose and cost, in plain numbers.

NA-931 is not injected

It is taken by mouth (oral capsule). Top dose in the company's 13-week phase 2, given as a once-daily capsule. No injectable dose exists; vials sold as NA-931 are grey-market products that have tested as other compounds.

Cost per month

—

Cost per dose

—

Typical dose

150 mg–150 mg / dayTrial dose

How do you store it?

Before mixing, and after.

Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.

Unmixed lyophilized NA-931 keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.

Not legally available outside clinical trials, so no prescriber is assessing whether it suits you
Pregnancy, or trying to become pregnant

Stop and get help

These are emergencies. Seek care.

Signs of an allergic reaction
Any severe or persistent symptom, because with grey-market vials the contents are unknown and testing has found three different compounds sold under this name

Common effects

Expected, and usually mild.

The company describes the phase 2 as well tolerated without publishing the detail
No independent safety data exists, so the real-world effect profile is unknown

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

Is NA-931 approved?

And where the numbers on this page come from.

No. NA-931 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

Approval status
Investigational
Route
By mouth (oral capsule)
Checked
23 September 2026
Dose
From published clinical trials. Not approved by a regulator for this dose.
Vial size
From what vendors typically list; not a recommendation.
Sources
Biomed Industries, NA-931 phase 3 press release ClinicalTrials.gov, NCT06564753 (phase 2)ClinicalTrials.gov, NCT06615700 and NCT06732245 Diabetes 2025;74(Suppl 1):143-OR (ADA abstract, NCT06615700)Biomed Industries, EASD 2025 press release Aus Aminos, Bioglutide investigation Independent analytical testing reports

What has happened recently

Not approved in any country. Phase 3 trials (120 mg once daily, alone and combined with oral semaglutide) were announced at the ADA meeting in June 2026, but no results have been published in a peer-reviewed journal. NA-931 has never been sold as an injectable by its developer; any vial labelled NA-931, Bioglutide or GLP-4 is an unregulated grey-market product, and independent tests of such vials have found a different compound every time.

You can compare this against the whole library, or read how to check a seller.

What else is like NA-931?

Others in GLP-1 agonists, side by side.

If you're weighing NA-931, it's worth reading Semaglutide, Tirzepatide, and Retatrutide in the same class.

YOU ARE HERE

NA931

NA-931

An experimental daily obesity capsule that has also become one of the most-faked names in the supply chain.

Investigational

Dose: Up to 150 mg once daily in the phase 2 trial
How often: Daily

SEMA

Semaglutide

The drug in Ozempic and Wegovy: a weekly shot that curbs hunger for steady weight loss.

FDA-approved

Dose: 0.25 up to 2.4 mg per week (start low, increase slowly)
How often: Weekly

TIRZ

Tirzepatide

The drug in Mounjaro and Zepbound: a weekly shot for major weight loss and blood sugar.

FDA-approved

Dose: 2.5 up to 15 mg per week (start low, increase slowly)
How often: Weekly

RETA

Retatrutide

An experimental weekly shot with some of the biggest weight-loss numbers yet in trials.

Investigational

Dose: 1 up to 12 mg per dose (start low, increase slowly)
How often: Weekly

See other GLP-1 receptor drugs

See how this compares to 14 other GLP-1 drugs

Guides for this compound

How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Semaglutide vs Tirzepatide vs Retatrutide
One receptor, two, or three. Mechanism, trial weight loss, side effects, and real cost.

Sources

Biomed Industries, NA-931 phase 3 press release(2026)
Describes NA-931 as an orally active small-molecule quadruple receptor agonist targeting IGF-1, GLP-1, GIP and glucagon; reports 13-week phase 2 weight reduction up to 13.8% at 150 mg daily against placebo. Company statement about its own unapproved product.
ClinicalTrials.gov, NCT06564753 (phase 2)(2026)
A 13-week randomised, double-blind, placebo-controlled study in adults with obesity or overweight with a comorbidity; sponsor Biomed Industries.
ClinicalTrials.gov, NCT06615700 and NCT06732245(2026)
A phase 1 study of 74 participants taking NA-931 capsules, and a later trial of NA-931 alongside tirzepatide.
Diabetes 2025;74(Suppl 1):143-OR (ADA abstract, NCT06615700)(2025)
28-day randomised, double-blind, placebo-controlled dose-escalation study in 74 overweight or obese participants: dose-dependent weight reduction up to 6.4%, up to 63% achieving at least 5% weight loss, and only mild gastrointestinal adverse events reported.
Biomed Industries, EASD 2025 press release(2025)
Records that the company's chief executive presented the phase 2 results at the EASD annual meeting in Vienna in September 2025.
Aus Aminos, Bioglutide investigation(2025)
A long investigation arguing that NA-931 does not exist and that the company's data were fabricated. The author sells peptides, so this is an interested party, and the allegations have not been tested by a court or regulator.
Independent analytical testing reports(2026)
Material sold as NA-931 by a Chinese supplier tested at NuMega Resonance Labs came back as cyclo(Pro-Gly), mass 154 daltons. An earlier Bioglutide product tested at Janoshik was a retatrutide and cagrilintide blend; a third sample was [D-Lys3]-GHRP-6. Not peer-reviewed; the underlying lab reports should be requested before relying on the detail.

Last reviewed 23 September 2026